Mumbai, April 10, 2019: Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC’s Fluoxetine Tablets, 60mg. It is indicated in the treatment of:
Adults: Efficacy was established in one 5-week trial, three 6-week trials, and one maintenance study Pediatrics: Efficacy was established in two 8- to 9-week trials of patients 8 to 18 years of age
Adults: Efficacy was established in two 13-week trials
Pediatrics: Efficacy was established in one 13-week trial in pediatric patients 7 to 17 years of age
Adults: Efficacy was established in two 8-week trials and one 16-week trial
Adults: Efficacy was established in two 12-week trials
Fluoxetine Tablets, 60mg, had annual sales of approximately USD 41 million in the US (IQVIA MAT February 2019).
Corporate Comm India(CCI Newswire)
By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…
Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Winter weather brings a host…
By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…
Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…
Coimbatore, October 30, 2024: Sri Ramakrishna Hospital’s Neurology experts observes “World Stroke Day” on October…
Launched for 1st time in India, ARTGPT is designed to address queries regarding A.R.T treatments Product created…